Please login to the form below

Not currently logged in
Email:
Password:

EMEA backs extended uses for Gardasil

The Committee for Medicinal Products for Human Use has given its backing for Sanofi Pasteur's application to extend the indications for its drug, Gardasil
The Committee for Medicinal Products for Human Use (CHMP) has given its backing for Sanofi Pasteur's application to extend the indications for its drug, Gardasil.

The European Medicines Agency (EMEA) has informed Sanofi Pasteur that the CHMP has recommended that the vaccine be used for the prevention of precancerous vaginal lesions caused by human papillomavirus (HPV) types 16 and 18.

Gardasil has been developed to prevent four different types of cervical cancer and is approved for use in 101 countries, with the drug having already been launched in 76 of them. It is currently approved in the EU for the inoculation of females aged between 9 and 26 for HPV types 6,11,16 and 18.

Elamr Joura, professor of gynaeco-oncology at the University of Vienna explained that precancerous vaginal lesions can be difficult to detect and are prone to recurrence.

"The treatment to avoid progression to cancer is challenging and often requires ablative therapy, partial vaginectomy and radiotherapy in the case of invasive cancer," Joura said.

"Women may suffer from anxiety, depression, sexual dysfunction and poor self-image, resulting in broken lives."

Sanofi Pasteur says that a decision on the extended marketing authorisation by the European Commission is expected within weeks.

Patrick Poirot, vice-president for medical and scientific affairs at Sanofi Pasteur, said: "This extension validates our comprehensive approach in addressing HPV-related genital diseases and our robust clinical development."

In March 2008, Sanofi Pasteur announced that results from clinical studies showed that Gardasil held an efficacy rate of 96 per cent. The Data and Safety Monitoring Board (DSMB) was prompted to recommend that the studies be stopped so women in the placebo group could be vaccinated with the drug.

3rd June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...
Emotional Intelligence and Blended Learning in Healthcare
EI and emotional selling are rising up the agenda when it comes to healthcare training. This article outlines how blended learning approaches can help put them into action....

Infographics